Zihipp Ltd is a UK-based biotechnology company established in 2012, currently registered under Reg: 08341001 and operating from their headquarters at Halo on the Bristol estate, BS1 6AJ. The company’s primary focus lies in researching and developing innovative therapies centered around gastrointestinal surgery for obesity and diabetes management. Zihipp distinguishes itself through a novel approach – minimizing surgical intervention while maximizing therapeutic impact. The core business involves preclinical research and development utilizing advanced technologies to optimize weight loss outcomes. Zi Hipp is classified as a small-to-medium sized company, with an international presence currently demonstrated by their website data indicating potential collaboration across Europe and North America. Currently, Zihipp operates under the Worker (A) visa status, signifying skilled worker employment within the UK’s immigration system. Their key areas of specialization are weight loss therapies designed to deliver benefits similar to gastric bypass surgery without the need for an invasive procedure. The company's activities fall under SIC codes related to biotechnology research and development, specifically those involving medical device innovation and pharmaceutical advancement.

Zihipp Ltd is a UK-based biotechnology company established in 2012, currently registered under Reg: 08341001 and operating from their headquarters at Halo on the Bristol estate, BS1 6AJ. The company’s primary focus lies in researching and developing innovative therapies centered around gastrointestinal surgery for obesity and diabetes management. Zihipp distinguishes itself through a novel approach – minimizing surgical intervention while maximizing therapeutic impact. The core business involves preclinical research and development utilizing advanced technologies to optimize weight loss outcomes. Zi Hipp is classified as a small-to-medium sized company, with an international presence currently demonstrated by their website data indicating potential collaboration across Europe and North America. Currently, Zihipp operates under the Worker (A) visa status, signifying skilled worker employment within the UK’s immigration system. Their key areas of specialization are weight loss therapies designed to deliver benefits similar to gastric bypass surgery without the need for an invasive procedure. The company's activities fall under SIC codes related to biotechnology research and development, specifically those involving medical device innovation and pharmaceutical advancement.